Erick Lucera Net Worth

The estimated Net Worth of Erick Lucera is at least $238 Thousand dollars as of 14 August 2024. Mr. Lucera owns over 39,266 units of Beyond Air stock worth over $16,872 and over the last 8 years he sold XAIR stock worth over $125,311. In addition, he makes $95,380 as Independent Director at Beyond Air.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

or

Sign up with Google Sign up with Facebook

Mr. Lucera XAIR stock SEC Form 4 insiders trading

Erick has made over 7 trades of the Beyond Air stock since 2017, according to the Form 4 filled with the SEC. Most recently he bought 39,266 units of XAIR stock worth $15,706 on 14 August 2024.

The largest trade he's ever made was buying 39,266 units of Beyond Air stock on 14 August 2024 worth over $15,706. On average, Erick trades about 3,355 units every 129 days since 2017. As of 14 August 2024 he still owns at least 43,608 units of Beyond Air stock.

You can see the complete history of Mr. Lucera stock trades at the bottom of the page.

Erick Lucera biography

Erick J. Lucera serves as Independent Director of the Company. He is the Chief Financial Officer of Valeritas, a U.S. NASDAQ traded commercial stage company developing new technology for diabetes. Mr. Lucera served as Chief Financial Officer, Treasurer and Secretary of Viventia Bio. From 2012 to 2015, he was Vice President, Corporate Development at Aratana Therapeutics, a veterinary biopharmaceutical company. While at Aratana, he helped grow the company’s product pipeline through a series of acquisitions and in licensing transactions financed through five public and private offerings of nearly $250 million. Before his career as a healthcare company executive, Mr. Lucera spent over 15 years in investment management as a healthcare analyst at Eaton Vance, the portfolio manager of the Triathlon Life Sciences Fund at Intrepid Capital and as head of the healthcare research team at Independence Investments. He holds a Certificate in Public Health from Harvard University, an MS in quantitative finance from Boston College, an MBA from Indiana University Bloomington, and a BS in accounting from the University of Delaware. Mr. Lucera has obtained CFA, CMA, and CPA designations. Erick’s financial and industry background serve us well on many fronts, including our audit committee.

What is the salary of Erick Lucera?

As the Independent Director of Beyond Air, the total compensation of Erick Lucera at Beyond Air is $95,380. There are 9 executives at Beyond Air getting paid more, with Steven Lisi having the highest compensation of $2,969,660.

How old is Erick Lucera?

Erick Lucera is 51, he's been the Independent Director of Beyond Air since 2017. There are 6 older and 6 younger executives at Beyond Air. The oldest executive at Beyond Air, Inc. is Michael A. Gaul, 65, who is the Sr. VP of Operations.

What's Erick Lucera's mailing address?

Erick's mailing address filed with the SEC is C/O BEYOND AIR, INC., 900 STEWART AVENUE, SUITE 301, GARDEN CITY, NY, 11530.

Insiders trading at Beyond Air

Over the last 5 years, insiders at Beyond Air have traded over $4,582,444 worth of Beyond Air stock and bought 3,519,117 units worth $12,396,434 . The most active insiders traders include Robert Carey, Steven A. Lisi, and Amir Avniel. On average, Beyond Air executives and independent directors trade stock every 17 days with the average trade being worth of $15,492. The most recent stock trade was executed by Steven A. Lisi on 15 August 2024, trading 50,000 units of XAIR stock currently worth $18,500.

What does Beyond Air do?

Beyond Air, Inc., a clinical-stage medical device and biopharmaceutical company, develops nitric oxide (NO) generator and delivery systems. The company is developing LungFit system, a NO generator and delivery system, which is in clinical trials for the treatment of persistent pulmonary hypertension of the newborn; acute viral pneumonia, including COVID-19; bronchiolitis and nontuberculous mycobacteria lung infections; and solid tumors. It operates in Israel, Ireland, Australia, and the European Union. The company was formerly known as AIT Therapeutics, Inc. and changed its name to Beyond Air, Inc. in June 2019. Beyond Air, Inc. is based in Garden City, New York.

Complete history of Mr. Lucera stock trades at AVEO Pharmaceuticals Inc, Editas Medicine Inc, and Beyond Air

Beyond Air executives and stock owners

Beyond Air executives and other stock owners filed with the SEC include:

• Steven Lisi,
  Chairman of the Board, Chief Executive Officer
• Amir Avniel,
  President, Chief Operating Officer, Director
• Adam Newman,
  Chief Legal Officer and General Counsel
• Steven Adam Lisi,
  CEO & Chairman
• Duncan Fatkin,
  Chief Commercial Officer
• Douglas Beck,
  Chief Financial Officer
• Amir Avniel,
  Co-Founder, Pres, COO & Director
• Douglas J. Beck CPA, CPA,
  Consultant
• William Forbes,
  Independent Director
• Erick Lucera,
  Independent Director
• Robert Carey,
  Independent Director
• Yoori Lee,
  Independent Director
• Ron Bentsur,
  Independent Director
• Bob Yedid,
  IR Contact Officer
• Prof. Andrew R. Colin M.D.,
  Chief Medical Officer & Member of Scientific Advisory Board
• Kori-Ann Taylor,
  Head of Marketing
• Rebecca Van Doren,
  Head of Sales
• Maria Yonkoski,
  Head of Investor Relations
• Douglas Quinton Larson,
  CFO, Principal Financial Officer & Principal Accounting Officer
• Hila Confino Ph.D.,
  Research Project Mang.
• Michael A. Gaul,
  Sr. VP of Operations
• Ali Ardakani,
  Sr. VP of Device & Bus. Devel.
• Dr. Giora Davidai M.D.,
  Chief Medical Officer
• Douglas Quinton Larson,
  Chief Financial Officer
• Michael A. Gaul,
  Chief Operating Officer
• Jeff Lynn Myers,
  Chief Medical Officer